This program is expected to influence the company’s market position by optimizing its capital structure and potentially boosting investor confidence. More about Novo Nordisk Novo Nordisk is a ...

The parent company of Danish drug maker Novo Nordisk said it completed its $ ... Telthorst also has said the company has an unusual ownership structure — it is owned by a foundation — and ...

The Novo Nordisk Foundation (NNF ... is the NIVI’s novel structure, combining a state-of-the-art research centre with a limited liability company, according to the NNF. That will help to ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

Let's find out. Novo Nordisk has been making breakthroughs in diabetes care for about 100 years. The company is still at it. As of August 2024, it had a 33.9% share of the diabetes care market ...